In patients with metastatic colorectal cancer (mCRC), the median progression-free survival of BIBF 1120 as a first-line treatment with mFOLFOX6 was 10.6 months. This efficacy is comparable to that of bevacizumab plus mFOLFOX6. Recently, at the 2011 European Multidisciplinary Oncology Conference (EMCC), a total of 126 patients were included in a randomized, two-stage, phase II clinical outcome.
Unlike other angiogenic kinase inhibitors that target only one receptor, BIBF 1120 is a novel inhibitor of three vascular kinases that simultaneously blocks three growth factor receptors (VEGFR 1-3, PDGFR-&alPHa; and Beta, FGFR 1-3). These three kinds of receptors play a key role in the formation and maintenance of new blood vessels. Blocking their effects can inhibit angiogenesis and eventually may prevent the growth and spread of tumors.
The study also showed that the objective remission rate (ORR) used to assess tumor shrinkage was 61.2% and 53.7% in the BIBF 1120 treatment group and the bevacizumab treatment group, respectively. At the 9th month, the progression-free survival rate of the BIBF 1120-treated group was similar to that of the bevacizumab-treated group, which was 63% and 69%, respectively. More importantly, only 34.1% of patients treated with BIBF 1120 had serious adverse events, compared with 53.7% of patients receiving bevacizumab.
It is reported that the study is still in progress to collect data on overall survival. In addition, BIBF 1120 has shown application potential in other types of tumors, and clinical phase III studies of lung and ovarian cancer are also underway.
Unlike other angiogenic kinase inhibitors that target only one receptor, BIBF 1120 is a novel inhibitor of three vascular kinases that simultaneously blocks three growth factor receptors (VEGFR 1-3, PDGFR-&alPHa; and Beta, FGFR 1-3). These three kinds of receptors play a key role in the formation and maintenance of new blood vessels. Blocking their effects can inhibit angiogenesis and eventually may prevent the growth and spread of tumors.
The study also showed that the objective remission rate (ORR) used to assess tumor shrinkage was 61.2% and 53.7% in the BIBF 1120 treatment group and the bevacizumab treatment group, respectively. At the 9th month, the progression-free survival rate of the BIBF 1120-treated group was similar to that of the bevacizumab-treated group, which was 63% and 69%, respectively. More importantly, only 34.1% of patients treated with BIBF 1120 had serious adverse events, compared with 53.7% of patients receiving bevacizumab.
It is reported that the study is still in progress to collect data on overall survival. In addition, BIBF 1120 has shown application potential in other types of tumors, and clinical phase III studies of lung and ovarian cancer are also underway.
Oxidized Regenerated Cellulose
Oxidized Regenerated Cellulose Absorbable Gauze,Oxidized Regenerated Cellulose Fibrillar,Absorbent Oxidized Regenerated Hemostats Cellulose,Medical Grade Oxidized Regenerated Cellulose
Shaoxing Aladdin Enterprise Co.,Ltd , https://www.xhemostat.com